Classifying new anti-tuberculosis drugs: rationale and future perspectives

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Accurate classification of anti-tuberculosis (TB) drugs is crucial for effective treatment regimens, particularly for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB.
• Previous World Health Organization (WHO) guidelines classified drugs based on efficacy and toxicity in a step-down manner (groups 1-5).
• Group 5 drugs previously had limited efficacy or clinical evidence, posing challenges in treatment selection.

Purpose of the Study:

• To describe the evolution of WHO's anti-TB drug classification system.
• To analyze recent changes in WHO guidance for managing drug-resistant TB.
• To compare the revised WHO classification with an independently proposed future classification system and discuss the latest evidence on ex-group 5 drugs.

Main Methods:

• Review and analysis of current WHO guidelines and evidence on anti-TB drugs.
• Comparison of the previous WHO classification system with the revised hierarchical system (groups A-D).
• Consideration of an independently proposed future drug classification for TB management.

Main Results:

• The WHO has revised its anti-TB drug classification, introducing a new hierarchical system (groups A-D) specifically for drug-resistant cases.
• This revised classification aims to provide a clearer framework for clinicians to build appropriate anti-TB regimens.
• An independently proposed future classification is also presented for discussion.

Conclusions:

• The revised WHO classification represents a significant update in managing drug-resistant TB, moving away from the previous step-down approach.
• Understanding the differences between the current and proposed classifications is essential for optimizing treatment strategies.
• Ongoing evaluation of evidence, especially for previously categorized drugs, is vital for refining TB drug regimens.